Vir Biotechnology, Inc.

BMV:VIR * Stock Report

Market Cap: Mex$22.5b

Vir Biotechnology Past Earnings Performance

Past criteria checks 0/6

Vir Biotechnology has been growing earnings at an average annual rate of 28.3%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 54.9% per year.

Key information

28.3%

Earnings growth rate

60.3%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth rate54.9%
Return on equity-35.9%
Net Margin-505.7%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vir Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:VIR * Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 23119-601174145
30 Jun 23491-2621760
31 Mar 23446-1441700
31 Dec 221,6165161620
30 Sep 222,3791,143139280
30 Jun 222,1081,0781470
31 Mar 222,3261,2161340
31 Dec 211,0955291210
30 Sep 21284-1021280
30 Jun 21183-297960
31 Mar 2173-390840
31 Dec 2076-299710
30 Sep 2076-257600
30 Jun 2075-220500
31 Mar 2010-223420
31 Dec 198-175380
30 Sep 1910-137330
30 Jun 1912-122310
31 Mar 1912-117300
31 Dec 1811-116290
31 Dec 173-70220

Quality Earnings: VIR * is currently unprofitable.

Growing Profit Margin: VIR * is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VIR * is unprofitable, but has reduced losses over the past 5 years at a rate of 28.3% per year.

Accelerating Growth: Unable to compare VIR *'s earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIR * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).

Return on Equity

High ROE: VIR * has a negative Return on Equity (-35.86%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/11 14:47
End of Day Share Price 2023/09/13 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vir Biotechnology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Huidong WangBarclays
Alec StranahanBofA Global Research